Moleculin Biotech (MBRX) Cash & Equivalents (2015 - 2026)

Moleculin Biotech's Cash & Equivalents history runs 11 years deep, the most recent figure standing at $8.9 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 107.53% year-over-year to $8.9 million; the TTM figure through Dec 2025 stood at $8.9 million (up 107.53% YoY), while the FY2025 annual figure was $8.9 million, up 107.53% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $8.9 million, up from $6.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $86.3 million in Q1 2021, with the low at $4.3 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $28.4 million (2023), against an average of $36.0 million.
• The sharpest annual moves came in 2021 and 2024: Cash & Equivalents soared 640.78% in 2021, then sank 81.83% in 2024.
• Moleculin Biotech's Cash & Equivalents stood at $70.9 million in 2021, then plunged by 39.15% to $43.1 million in 2022, then sank by 45.42% to $23.6 million in 2023, then tumbled by 81.83% to $4.3 million in 2024, then jumped by 107.53% to $8.9 million in 2025.
• Business Quant data shows MBRX's Cash & Equivalents at $8.9 million in Q4 2025, $6.7 million in Q3 2025, and $7.6 million in Q2 2025.